Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltd Live Price Chart
Performance
| Previous Close | ₹ 979.9 |
| High | ₹ 999.7 |
| Volume | 1916 |
| 52W Range | ₹ 960.3 - ₹ 1073.9 |
| Open | ₹ 983 |
| Low | ₹ 959 |
| Market Cap | ₹ 456.86 Cr |
Jenburkt Pharmaceuticals Ltd Technicals
| 20 Day | ₹ 1,025.046 |
| 50 Day | ₹ 1,053.709 |
| 100 Day | ₹ 1,072.285 |
| 200 Day | ₹ 1,086.673 |
| 20 Day | ₹ 1,029.073 |
| 50 Day | ₹ 1,059.473 |
| 100 Day | ₹ 1,098.784 |
| 200 Day | ₹ 1,077.364 |
Jenburkt Pharmaceuticals Ltd Fundamentals
| ROCE | 23.196 |
| P/E Ratio | 13.150 |
| P/B Ratio | 2.190 |
| Industry P/E | 2.190 |
| Debt to Equity | 51.202 |
| ROE | 17.629 |
| EPS | 74.390 |
| Dividend Yield | 2.110 |
| Book Value | 446.469 |
| Face Value | 10.000 |
Jenburkt Pharmaceuticals Ltd Financials
| Particulars | Y202603 | Y202503 | Y202403 | Y202303 | Y202203 |
|---|---|---|---|---|---|
| Total Revenue | 179.0401 | 158.4125 | 146.6334 | 141.8724 | 128.9291 |
| Total Expenses | 128.5701 | 114.4797 | 111.4575 | 109.0077 | 99.0582 |
| Profit After Tax | 34.736 | 32.0606 | 25.9773 | 24.607 | 22.2972 |
Jenburkt Pharmaceuticals Ltd Shareholding Pattern
| Promoter Holdings | 46.619 % |
| FIIs | 0.000 % |
| DIIs | 0.121 % |
| MutualFund | 0.000 % |
| Retail | 41.054 % |
| Others - | 12.205 % |
About Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Limited was formed a joint venture to diversify into the healthcare and pharmaceutical industry, by Bhuta family during the period 1986. The Company engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products. It works more than 1,000 stockists and their reach extends to 400,000+ pharmacies across the globe. The organisation serve to government, semi-government institutions, missionary hospitals, public sector enterprises, etc. The purpose of the Company is to serve those in need of quality healthcare by bringing revolutionary, life-changing therapeutic solutions that are accessible to all. Way back in the 20th century, a visionary in the field of healthcare and philanthropic work - Shri Nandlal Mulji Bhuta laid the foundation for several groups of companies. Continuing the legacy of Shri Nandlal Mulji Bhuta, his sons Mr. Uttam N. Bhuta and Mr. Hemendra N. Bhuta founded the Company. In 2021-22, the Company launched a new OTC division ~ Jenburkt Wellness towards better physical and mental health. The first brand launched was Zixa Strong, natural, pain relief product. Further, it launched Nervijen D3 tablets in 2022-23. Nervijen D3 tablets became the first brand in 2025 to reach a revenue target exceeding during the year. FY 2026 saw genuine distinction while the Company launched Cartisafe Forte, India's first fixed-dose combination of Undenatured Type II Collagen (40 mg), Glucosa ...
Similar Stocks
| Ambalal Sarabhai Enterprises Ltd Pharmaceuticals | ₹ 39.39 -0.58 (-1.45%) |
| Amrutanjan Health Care Ltd Pharmaceuticals | ₹ 493.80 +0 (+0%) |
| Astrazeneca Pharma India Ltd Pharmaceuticals | ₹ 6,714.00 -37.5 (-0.56%) |
| Bliss GVS Pharma Ltd Pharmaceuticals | ₹ 670.00 -11.85 (-1.74%) |
| Abbott India Ltd Pharmaceuticals | ₹ 26,895.00 -375 (-1.38%) |
| Cipla Ltd Pharmaceuticals | ₹ 1,390.00 -4.5 (-0.32%) |
FAQs on Jenburkt Pharmaceuticals Ltd
1. Can I buy Jenburkt Pharmaceuticals Ltd from PL Capital? ›
2. Does Jenburkt Pharmaceuticals Ltd pay dividends? ›
3. What is the current share price of Jenburkt Pharmaceuticals Ltd ? ›
4. What is the 52-week high and low of Jenburkt Pharmaceuticals Ltd ? ›
5. What is the market capitalisation of Jenburkt Pharmaceuticals Ltd? ›
6. What is the current P/E ratio of Jenburkt Pharmaceuticals Ltd? ›
7. What is the current P/B ratio of Jenburkt Pharmaceuticals Ltd? ›
8. What is the shareholding pattern of Jenburkt Pharmaceuticals Ltd? ›
9. What is the 1-year return of Jenburkt Pharmaceuticals Ltd? ›
Start SIP in Jenburkt Pharmaceuticals Ltd
Invest systematically in stocks with the
PL Capital app
Are you a new user? Open your account
